Quince Therapeutics, Inc. current report, 16 June 2021

SEC Filing Summary: Cortexyme, Inc. (CRTX)

Business Context and Reporting Period

This Form 8-K reports the results of the Annual Meeting of Stockholders held on June 16, 2021. The registrant is Cortexyme, Inc., a Delaware corporation headquartered in South San Francisco, California. The filing covers corporate governance matters submitted to a vote by security holders.

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on voting outcomes and does not contain financial performance data.

Material Changes and Voting Results

Approximately 90.4% of eligible shares (26,743,034 shares) were present or represented by proxy at the meeting. The following proposals were approved:

  • Election of Directors: Stockholders approved the election of Stephen S. Dominy, M.D., and David A. Lamond as Class II directors for three-year terms.
  • Ratification of Auditors: Stockholders ratified the appointment of BDO USA, LLP as the independent registered accounting firm for the fiscal year ending December 31, 2021.
  • Executive Compensation (Say-on-Pay): Stockholders approved, on an advisory basis, the compensation of named executive officers.
  • Frequency of Say-on-Pay Votes: Stockholders indicated a preference for annual advisory votes on executive compensation. The Board has determined to conduct these votes every year until the 2027 Annual Meeting.

Guidance, Outlook, and Risks

The filing text does not provide a clear value for future guidance, management outlook, specific risks, contingencies, or unusual items. The document is limited to the disclosure of voting results.

Key Facts for Investor Verification

  • Verify the final composition of the Board of Directors following the election of the two Class II directors.
  • Confirm the engagement of BDO USA, LLP for the 2021 fiscal year audit.
  • Note the significant number of votes against the executive compensation proposal (7,779,512 votes against vs. 14,994,212 votes for), indicating notable shareholder dissent on pay.
  • Confirm the company's commitment to annual say-on-pay votes as per the new policy.